 Impel NeuroPharma Inc. NASDAQ: IMPL secured U.S. FDA approval for its Trudhesa nasal spray as an acute treatment of migraine in adults with or without aura. Shares of the company opened more than 40 up on Friday but lost the entire gain later on. 